Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 13/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22916883 | 0.65 | NPC1 (0.41) | HDAC1HDAC8HDAC6NLRP3 | |
| SCHEMBL18629308 | 0.63 | HDAC1 (0.40) | HDAC1HDAC8HDAC6NLRP3KLKB1 | |
| SCHEMBL21066334 | 0.61 | HDAC1 (0.45) | HDAC1 | |
| SCHEMBL15053076 | 0.60 | KDM4E (0.46) | HDAC1 | |
| SCHEMBL23021251 | 0.59 | HDAC1 (0.37) | HDAC1HDAC8HDAC6NLRP3KLKB1 | |
| SCHEMBL3539633 | 0.59 | ELANE (0.37) | HDAC1HDAC8HDAC6NLRP3KLKB1 | |
| SCHEMBL3370259 | 0.59 | ELANE (0.37) | HDAC1HDAC8HDAC6NLRP3 | |
| SCHEMBL26333020 | 0.59 | MAPT (0.65) | — | |
| SCHEMBL18938321 | 0.59 | — | — | |
| SCHEMBL554753 | 0.58 | KLKB1 (0.50) | HDAC1HDAC8HDAC6KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20210024540-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024540-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | HDAC1 6/4885HDAC8 14/4885HDAC6 25/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | HDAC1 6/4885HDAC8 14/4885HDAC6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.